trending Market Intelligence /marketintelligence/en/news-insights/trending/hR5HZMIi7VXaFyCMx9z-dQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Boston Scientific to acquire remaining stake in heart implant maker for $325M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Boston Scientific to acquire remaining stake in heart implant maker for $325M

Boston Scientific Corp. exercised its option to acquire the remaining stake in Millipede Inc. for $325 million to expand its portfolio of heart devices.

In January, Marlborough, Mass.-based Boston picked up a minority stake in Millipede for $90 million and was given the option to fully acquire the privately held medical device maker if Millipede successfully completed a first-in-human clinical study.

Santa Rosa, Calif.-based Millipede is developing a device called IRIS transcatheter annuloplasty ring system to treat patients with severe mitral regurgitation who cannot have open heart surgery. Mitral regurgitation is a condition in which the heart's mitral valve does not close tightly, which allows the blood to flow backward in the heart.

The system uses a procedure to tighten or reinforce the ring around the valve in the heart, which reduces the size of the dilated mitral annulus. IRIS, which is delivered by a transcatheter-transseptal delivery system, can be used as a stand-alone device or in combination with other technologies.

Millipede is also eligible for an additional $125 million if it achieves a certain commercial milestone.

The deal is expected to close in the first quarter of 2019, subject to customary closing conditions.